02981nas a2200505 4500008004100000022001400041245012200055210006900177260001300246300001200259490000700271520155500278653000901833653002201842653001501864653001801879653002601897653002801923653002701951653002201978653003102000653001102031653001302042653001102055653001102066653001202077653002302089653000902112653002302121653002202144653001602166653003602182100001802218700002202236700001802258700001802276700002402294700001902318700002002337700001802357700002402375700002002399700002002419856003602439 2015 eng d a1532-860000aAssociations between metabolic dysregulation and circulating biomarkers of fibrosis: the Cardiovascular Health Study.0 aAssociations between metabolic dysregulation and circulating bio c2015 Oct a1316-230 v643 a
AIM: Fibrosis is one postulated pathway by which diabetes produces cardiac and other systemic complications. Our aim was to determine which metabolic parameters are associated with circulating fibrosis-related biomarkers transforming growth factor-β (TGF-β) and procollagen type III N-terminal propeptide (PIIINP).
METHODS: We used linear regression to determine the cross-sectional associations of diverse metabolic parameters, including fasting glucose, fasting insulin, body mass index, fatty acid binding protein 4, and non-esterified fatty acids, with circulating levels of TGF-β (n = 1559) and PIIINP (n = 3024) among community-living older adults in the Cardiovascular Health Study.
RESULTS: Among the main metabolic parameters we examined, only fasting glucose was associated with TGF-β (P = 0.03). In contrast, multiple metabolic parameters were associated with PIIINP, including fasting insulin, body mass index, and non-esterified fatty acids (P<0.001, P<0.001, P=0.001, respectively). These associations remained statistically significant after mutual adjustment, except the association between BMI and PIIINP.
CONCLUSIONS: Isolated hyperglycemia is associated with higher serum concentrations of TGF-β, while a broader phenotype of insulin resistance is associated with higher serum PIIINP. Whether simultaneous pharmacologic targeting of these two metabolic phenotypes can synergistically reduce the risk of cardiac and other manifestations of fibrosis remains to be determined.
10aAged10aAged, 80 and over10aBiomarkers10aBlood Glucose10aCardiovascular System10aCross-Sectional Studies10aDiabetes Complications10aDiabetes Mellitus10aFatty Acids, Nonesterified10aFemale10aFibrosis10aHealth10aHumans10aInsulin10aInsulin Resistance10aMale10aMetabolic Diseases10aPeptide Fragments10aProcollagen10aTransforming Growth Factor beta1 aAgarwal, Isha1 aGlazer, Nicole, L1 aBarasch, Eddy1 aDjoussé, Luc1 aGottdiener, John, S1 aIx, Joachim, H1 aKizer, Jorge, R1 aRimm, Eric, B1 aSiscovick, David, S1 aKing, George, L1 aMukamal, Ken, J uhttps://chs-nhlbi.org/node/6805